Clinical trials
Unresectable clinical trials
Below are recruiting unresectable clinical trials, each written for real people, not researchers. We’re tracking 461 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06244771RecruitingPhase 1/Phase 2
Testing FMC-376 for KRAS G12C mutated solid tumors
This study tests a new targeted pill called FMC-376 for people whose cancer has a specific KRAS G12C mutation. The goal is to see if it can shrink tumors or slow their growth when other treatments have stopped working.
La Jolla, CaliforniaAges 18 years+ - NCT06244225RecruitingPhase 2
Triple therapy for advanced liver cancer (HAIC + sintilimab + donafenib)
This trial tests a combination of three treatments for advanced liver cancer that cannot be removed by surgery: a targeted oral drug (Donafenib), an immunotherapy (Sintilimab), and a type of chemotherapy given directly into the liver artery. The goal is to see if this triple therapy works better than current options for people who have not had any prior cancer treatment.
Wuhan, HubeiAges 18 years+ - NCT06256588RecruitingPhase 3
Dostarlimab vs placebo after chemoradiation for head and neck cancer
This study tests whether the immunotherapy drug dostarlimab, given after standard chemoradiation, can keep advanced head and neck cancer from coming back. It is for people who have not had surgery and whose tumors are PD-L1 positive.
Jonesboro, ArkansasAges 18 years+ - NCT06265025RecruitingPhase 1/Phase 2
GM103 injection for advanced solid tumors that can't be removed
This trial tests an experimental drug called GM103 that is injected directly into tumors. It is for people with advanced solid tumors that have not responded to other treatments and cannot be surgically removed.
Goyang-si, Gyeonggi-doAges 18 years+ - NCT06274879RecruitingPhase 2
Radiofrequency ablation for bile duct cancer
This trial tests a procedure that uses heat (radiofrequency ablation) to treat bile duct cancer that can't be removed by surgery. If you have this type of cancer and are starting standard treatment, this study wants to see if adding this heat treatment is safe and might help.
BernAges 18 years+ - NCT06279364RecruitingPhase 3
Testing SKB264 vs standard chemo for advanced triple-negative breast cancer
This trial tests a new drug called SKB264 against standard chemotherapy options for people with advanced triple-negative breast cancer who have not yet received chemotherapy for their advanced disease. The goal is to see if SKB264 works better than the usual treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06284590RecruitingPhase 2
Injected immunotherapy plus pembrolizumab for resistant melanoma
This study tests a new approach for advanced melanoma that is not responding to standard immunotherapy (like pembrolizumab). It combines a targeted injection directly into the tumor (L19IL2, L19TNF, or both) with pembrolizumab. The goal is to see if this combination can shrink tumors and help the immune system fight the cancer.
New York, New YorkAges 18 years+ - NCT06298968RecruitingPhase 2
Study of chemo, targeted therapy, and immunotherapy for bile duct cancer
This trial tests a combination of chemotherapy (gemcitabine and cisplatin) with the targeted therapy lenvatinib and the immunotherapy adebrelimab for people with advanced bile duct cancer that cannot be removed by surgery. It aims to see if this combination works better than standard treatments.
Guangzhou, GuangdongAges 18–75 - NCT06302621RecruitingPhase 1
Pemigatinib plus afatinib for advanced solid tumors with FGFR changes
This trial tests two targeted drugs, pemigatinib and afatinib, together for people with advanced solid tumors that have a specific FGFR genetic change. It may be an option if standard treatments have stopped working or aren't available.
Boston, MassachusettsAges 18 years+ - NCT06312176RecruitingPhase 3
Study of new drugs for HR+/HER2- advanced breast cancer
This trial tests two new drugs (sacituzumab tirumotecan and pembrolizumab) against standard treatments for a type of advanced breast cancer that is hormone receptor positive and HER2 negative. It's for people whose cancer has worsened despite hormone therapy with a CDK4/6 inhibitor.
Chandler, ArizonaAges 18 years+ - NCT06324240RecruitingPhase 1
Personalized vaccine plus immunotherapy for triple-negative breast cancer
This trial tests a personalized vaccine made from your tumor combined with immunotherapy drugs (pembrolizumab or ipilimumab) for triple-negative breast cancer. It aims to help your immune system recognize and attack cancer cells.
Atlanta, GeorgiaAges 18 years+ - NCT06339424RecruitingPhase 2
Atezolizumab and Bevacizumab with radiation for liver cancer that can't be removed
This trial tests adding two immunotherapy and anti-angiogenesis drugs (atezolizumab and bevacizumab) to standard photon radiation for people with liver cancer that cannot be surgically removed. It aims to see if this combination can shrink tumors and improve outcomes.
Taoyuan City, TaiwanAges 18 years+ - NCT06375486RecruitingPhase 2
Ivonescimab and HAIC for Unresectable Liver Cancer
This trial tests a combination of a targeted immunotherapy drug (ivonescimab) and a liver-directed chemotherapy infusion (HAIC) for people with liver cancer that cannot be removed by surgery. It may be an option if you have not had prior systemic treatment for your liver cancer.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06406634RecruitingPhase 2
Cadonilimab, Lenvatinib, and HAIC for Unresectable Liver Cancer
This trial tests a combination of three treatments for advanced liver cancer that can't be removed by surgery. It uses an immunotherapy drug (cadonilimab), a targeted therapy pill (lenvatinib), and a direct chemotherapy infusion into the liver (HAIC). The goal is to see if this combo can shrink tumors and improve outcomes.
Changsha, HunanAges 18–75 - NCT06410651RecruitingPhase 2
Nimotuzumab with chemoradiation for advanced esophageal cancer
This trial tests adding the targeted drug nimotuzumab to standard chemotherapy and radiation for people with esophageal cancer that cannot be removed by surgery. It may help shrink the tumor or stop it from growing further.
BeijingAges 18–80 - NCT06414590RecruitingPhase 2
Tebentafusp before surgery for eye melanoma
This trial tests a drug called Tebentafusp for a type of eye melanoma (uveal melanoma) that is too large to be removed without taking out the whole eye. The goal is to see if the drug can shrink the tumor before deciding on surgery.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06428045RecruitingPhase 1
STARLITE for hard-to-surgery high-grade brain tumors
This trial tests a new treatment called STARLITE for people with fast-growing brain tumors (high-grade gliomas) that cannot be safely removed with surgery. The treatment uses a laser to destroy the tumor from the inside. It may be a good option if you haven't had any prior treatment for this tumor.
Miami, FloridaAges 18 years+ - NCT06430658RecruitingPhase 2
Combination treatment before surgery for unresectable esophageal cancer
This trial tests a combination of treatments given before surgery to shrink tumors in patients with esophageal cancer that is considered too advanced for immediate surgery. The goal is to make surgery possible and improve outcomes.
BeijingAges 18–75 - NCT06434064RecruitingPhase 2
Tamoxifen and chemotherapy for triple negative breast cancer
This trial tests a combination of tamoxifen (a hormonal therapy) and pegylated liposomal doxorubicin (a type of chemotherapy) for people with triple negative breast cancer that has spread or cannot be removed by surgery. It aims to see if this combination can help people whose cancer has not responded to at least two prior treatments.
Buffalo, New YorkAges 18 years+ - NCT06439836RecruitingPhase 1
Combination immunotherapy for advanced bladder cancer
This trial tests a new drug, CA-4948, combined with pembrolizumab (Keytruda) for people with advanced bladder cancer that grew after prior immunotherapy. The goal is to see if this combination can help when standard treatments stop working.
Duarte, CaliforniaAges 18 years+ - NCT06440993RecruitingPhase 2
Durvalumab with bile duct heat therapy for bile duct cancer
This trial tests a combination of a drug (durvalumab) that helps your immune system fight cancer, plus a special heat treatment applied inside the bile duct. It is for people with bile duct cancer that cannot be removed by surgery and who need a stent to open the bile duct.
AachenAges 18 years+ - NCT06446154RecruitingPhase 2
Fruquintinib after immunotherapy for advanced liver cancer
This trial tests a new drug called fruquintinib for people with advanced liver cancer who have already tried immunotherapy. It may help shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18 years+ - NCT06479239RecruitingPhase 1/Phase 2
Immune cell therapy for advanced pancreatic cancer
This trial tests a new immune cell therapy (EGFRBi armed PBMC) for people with advanced pancreatic cancer that can't be removed by surgery. It aims to see if this treatment can help control the cancer after you've already tried at least one type of chemotherapy and your disease is stable or better.
Charlottesville, VirginiaAges 18 years+ - NCT06493734Recruiting
SBRT after chemotherapy for inoperable bile duct cancer
This trial tests if a precise type of radiation (SBRT) can help people with inoperable bile duct cancer after they finish chemotherapy. It aims to control the tumor and improve outcomes.
Wilrijk, AntwerpAges 18 years+
Hear when a new Unresectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for unresectable?
- Yes. Clin2 currently lists 461 recruiting unresectable studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a unresectable trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a unresectable trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.